ReviewMolecules (Basel, Switzerland)2021
Thrombolytic Agents: Nanocarriers in Targeted Release.
Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Blood cell membrane camouflaged probiotic-powered micro-robot for dual-targeted thrombus therapy.Materials today. Bio · 2026Article
- Self-assembling nanocomposites for smart drug delivery: towards personalized and stimuli-responsive therapeutics.RSC advances · 2026Review
- Cellular and molecular mechanisms of thrombosis and thrombus-targeted thrombolytic strategies.Materials today. Bio · 2025Review
- Engineered Probiotic-Powered Micro-Rod Robot Bomb for Thrombus-Penetrating Explosion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Novel thrombolytic protease from the rare halophile Brachybacterium paraconglomeratum: bioprocessing and in vitro application.BMC biotechnology · 2025Article
- Dual-responsive and NIR-triggered detachable nanoplatform for integrated thrombolytic and antiplatelet therapy.Asian journal of pharmaceutical sciences · 2025Article
- Optimization and characterization of collagenase KU665299 and its application in effective in-vitro clot digestion.Biotechnology letters · 2025Article
- Mechanical Biomimetic Nanocomposites for Multidimensional Treatment of Arterial Thrombosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Response surface methodology to optimize theJournal of food science and technology · 2025Article
- Photothrombolytics: A light-driven technology for the targeted lysis of thrombi.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Nano-Drug Delivery Systems Targeting MMPs: A Promising Treatment for Gliomas.International journal of nanomedicine · 2025Review
- Review
- Progress of nanomaterials in the treatment of thrombus.Drug delivery and translational research · 2024Review
- Nanosystems in Cardiovascular Medicine: Advancements, Applications, and Future Perspectives.Pharmaceutics · 2023Review
- RGD peptide modified RBC membrane functionalized biomimetic nanoparticles for thrombolytic therapy.Journal of materials science. Materials in medicine · 2023Article
- Clot-targeted magnetic hyperthermia permeabilizes blood clots to make them more susceptible to thrombolysis.Journal of thrombosis and haemostasis : JTH · 2022Article
- In Vitro Antithrombotic, Hematological Toxicity, and Inhibitor Studies of Protocatechuic, Isovanillic, andMolecules (Basel, Switzerland) · 2022Article
- Nanomaterials as Ultrasound Theragnostic Tools for Heart Disease Treatment/Diagnosis.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
A thrombus, known as a blood clot, may form within the vascular system of the body and impede blood flow. Thrombosis is the most common underlying pathology of cardiovascular diseases, contributing to high morbidity and mortality. However, the main thrombolytic drugs (urokinase, streptokinase, etc.) have shortcomings, including a short half-life, serious side effects and a lack of targeting, that limit their clinical application. The use of nano-drug delivery systems is expected to address these problems and a variety of approaches, including biological and physical responsive systems, have been explored. In this report, recent advances in the development of targeted nano-drug delivery systems are thoroughly reviewed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.